NXL NEXALIN TECHNOLOGY INC

Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21

Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21

ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW).

The exclusive event will feature Nexalin’s CEO Mark White, who will provide an in-depth overview of the company’s differentiated approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. White will highlight Nexalin’s expanding body of clinical evidence—including peer-reviewed studies and collaborations with leading institutions such as UC San Diego—while outlining progress across its next-generation product portfolio, including the Gen-3 HALO™ Clarity headset and integrated Virtual Clinic platform designed to enable scalable, physician-supervised, at-home treatment. With multiple international regulatory clearances in place and U.S. clinical and regulatory initiatives advancing, Nexalin is executing a clear pathway toward global commercialization. The presentation will also detail how Nexalin’s patented technology, real-time AI-enabled patient monitoring, and growing international footprint position the Company to capitalize on the rapidly expanding mental health and neurostimulation markets.

A live question and answer session will follow the presentation.

To register for the free webinar, please visit:

Questions can be pre-submitted to or online during the live event.

About Nexalin Technology, Inc.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman and Israel. Additional information about the Company is available at: .   

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 34 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, Cidara Therapeutics, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

Sign Up for RedChat

RedChat™ is an AI-powered investment research assistant designed to give investors instant access to critical insights from SEC filings, press releases, and corporate disclosures. Built to streamline small-cap and microcap stock research, RedChat analyzes thousands of public company documents and delivers clear, context-rich answers to investor questions in seconds. Instead of manually reviewing lengthy filings, investors can simply ask RedChat about financial results, partnerships, business strategy, or recent announcements and receive precise, source-based summaries. Investors can experience RedChat and start exploring stocks today at or .

To learn more about RedChip's products and services, please visit: .

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: 

Follow RedChip on Facebook: 

Follow RedChip on Instagram: 

Follow RedChip on Twitter: 

Follow RedChip on YouTube: 

Follow RedChip on Rumble: 

Subscribe to our Mailing List: 

Contact:

Dave Gentry

RedChip Companies Inc.

1-407-644-4256 | 1-800-REDCHIP (733-2447)





EN
14/04/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEXALIN TECHNOLOGY INC

 PRESS RELEASE

Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadershi...

Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China Company Designing FDA Application Amendments and U.S. Clinical Strategy Leveraging Extensive Real-World Neurostimulation Data Sets Reflecting Broad Clinical Experiences HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announced the successful completion of a series of high-level meetings in the United States and China focused on ad...

 PRESS RELEASE

Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on Apri...

Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21 ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW). The exclusive event will feature Nexalin’s CEO Mark White, who will provide an in-depth overview of the company’s differentiated approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. White will highlight Nexalin’s expanding body of clinical evidence—including pe...

 PRESS RELEASE

Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Tech...

Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with brain-network findings further supporting Nexalin’s differentiated, non-invasive DIFS approach Publication adds to Nexalin’s growing body of peer-reviewed evidence across insomnia and depression, TBI and PTSD, Alzheimer’s disease and ADHD Houston, TX, April 09, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: NXL) (the “Company” or “Ne...

 PRESS RELEASE

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De No...

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market 150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission for Drug-Free Insomnia Treatment Builds on Prior Peer-Reviewed Clinical Data and International Regulatory Approvals HOUSTON, TX, Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced continued adva...

 PRESS RELEASE

Nexalin Participates in and Commends Recent Congressional Momentum Sup...

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders Multiple new federal actions highlight deep brain neurostimulation as a high-priority emerging therapy for TBI, PTSD, stroke recovery, and Alzheimer’s disease HOUSTON, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: NXL) (the “Company” or “Nexalin”), developer of Deep Intracranial Frequency Stimulation (DIFS™) technology for non-invasive deep brain stimulation, commended the recent series of bipartisan Congressional initiatives expand...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch